Home
NICE Guidance
Conditions and diseases
Digestive tract conditions
Colorectal cancer
Explore
Register as a stakeholder
Show sections
11 new
and
1 updated
products since January 2017.
NICE Pathways - mapping our guidance
Colonoscopic surveillance
Colorectal cancer
Gastrointestinal cancers
Lung cancer
Suspected cancer recognition and referral
Technology appraisal guidance
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
(TA307)
March 2014
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
(TA118)
January 2007
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
(TA212)
December 2010
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer
(TA100)
April 2006
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
(TA439)
March 2017
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy
(TA242)
January 2012
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
(TA61)
May 2003
Laparoscopic surgery for colorectal cancer
(TA105)
August 2006
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
(TA240)
December 2011
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)
(TA334)
February 2015
Trifluridine–tipiracil for previously treated metastatic colorectal cancer
(TA405)
August 2016
Quality standards
Colorectal cancer
(QS20)
August 2012
Suspected cancer
(QS124)
June 2016
NICE
Guidelines
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas
(CG118)
March 2011
Colorectal cancer: diagnosis and management
(CG131)
November 2011
Improving outcomes in colorectal cancer
(CSG5)
June 2004
Suspected cancer: recognition and referral
(NG12)
June 2015
Interventional procedures guidance
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique)
(IPG56)
April 2004
Computed tomographic colonography (virtual colonoscopy)
(IPG129)
June 2005
Endoscopic full thickness removal of non-lifting colonic polyps
(IPG580)
May 2017
Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer
(IPG532)
September 2015
Preoperative high dose rate brachytherapy for rectal cancer
(IPG531)
August 2015
Radiofrequency ablation for colorectal liver metastases
(IPG327)
December 2009
Selective internal radiation therapy for non-resectable colorectal metastases in the liver
(IPG401)
July 2011
Transanal total mesorectal excision of the rectum
(IPG514)
March 2015
Diagnostics guidance
Molecular testing strategies for Lynch syndrome in people with colorectal cancer
(DG27)
February 2017
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy
(DG28)
May 2017
NICE
Medtech innovation briefings
OSNA for colon cancer staging
(MIB77)
August 2016
In development
Colon cancer (adjuvant) - irinotecan [ID379]
(GID-TAG380)
TBC
Technology appraisal guidance
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
(GID-TA10065)
TBC
Technology appraisal guidance
Colorectal cancer: diagnosis and management (update)
(GID-NG10060)
October 2019
NICE guidelines
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
(GID-TA10151)
August 2018
Technology appraisal guidance
Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
(GID-TA10165)
April 2018
Technology appraisal guidance
Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]
(GID-TA10110)
TBC
Technology appraisal guidance
Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care
(GID-DG10005)
July 2017
Diagnostics guidance
Guidance
Resources
Savings and productivity
Local practice